Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIa Study of RItuximab and VArlilumab in Relapsed or Refractory B-cell Malignancies

NCT03307746 is registered in ClinicalTrials.gov with University Hospital Southampton NHS Foundation Trust as lead sponsor.

NCT NCT03307746
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03307746 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIa Study of RItuximab and VArlilumab in Relapsed or Refractory B-cell Malignancies
Lead sponsor
University Hospital Southampton NHS Foundation Trust
Phase
Phase 1/2
Overall status
Completed
Start date
November 23, 2017
Completion date
August 21, 2024
Enrollment
26 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

b cell lymphoma